Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity - PubMed (original) (raw)

Review

Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity

C Hahmann et al. Cell Mol Life Sci. 2010 Jan.

Abstract

The emerging critical implications of Rho/Rho-kinase (ROCK) signaling in neurodegenerative diseases, glaucoma, renoprotection, diabetes and cancer have sparked growing interest in the pharmacological potential of ROCK inhibitors beyond their current application in cardiovascular disease. This article discusses the therapeutic benefits of novel ROCK inhibitors in development, and highlights the recent advances in the current understanding of disease-dependent and isoform-specific functions of ROCK and their potential impact on future therapeutic strategies.

PubMed Disclaimer

Similar articles

• 2,3-Diaminopyrazines as Rho kinase inhibitors.
  Henderson AJ, Hadden M, Guo C, Douglas N, Decornez H, Hellberg MR, Rusinko A, McLaughlin M, Sharif N, Drace C, Patil R. Henderson AJ, et al. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1137-40. doi: 10.1016/j.bmcl.2009.12.012. Epub 2009 Dec 5. Bioorg Med Chem Lett. 2010. PMID: 20022494
• ROCK-2-selective targeting and its therapeutic outcomes.
  Sharma P, Roy K. Sharma P, et al. Drug Discov Today. 2020 Feb;25(2):446-455. doi: 10.1016/j.drudis.2019.11.017. Epub 2019 Dec 12. Drug Discov Today. 2020. PMID: 31837997 Review.
• The Application of Rho Kinase Inhibitors in the Management of Glaucoma.
  Liu LC, Chen YH, Lu DW. Liu LC, et al. Int J Mol Sci. 2024 May 21;25(11):5576. doi: 10.3390/ijms25115576. Int J Mol Sci. 2024. PMID: 38891764 Free PMC article. Review.
• Rho-kinase inhibitors in the management of glaucoma.
  Berrino E, Supuran CT. Berrino E, et al. Expert Opin Ther Pat. 2019 Oct;29(10):817-827. doi: 10.1080/13543776.2019.1670812. Epub 2019 Oct 1. Expert Opin Ther Pat. 2019. PMID: 31573364 Review.
• Rho kinase inhibitors: potential treatments for diabetes and diabetic complications.
  Zhou H, Li YJ. Zhou H, et al. Curr Pharm Des. 2012;18(20):2964-73. doi: 10.2174/138161212800672688. Curr Pharm Des. 2012. PMID: 22571664 Review.

Cited by

• Antibiotic bone cement accelerates diabetic foot wound healing: Elucidating the role of ROCK1 protein expression.
  Yang C, Wang D. Yang C, et al. Int Wound J. 2024 Apr;21(4):e14590. doi: 10.1111/iwj.14590. Int Wound J. 2024. PMID: 38531354 Free PMC article. Clinical Trial.
• The Role of Rho Kinase Inhibitors in Corneal Diseases.
  Futterknecht S, Chatzimichail E, Gugleta K, Panos GD, Gatzioufas Z. Futterknecht S, et al. Drug Des Devel Ther. 2024 Jan 19;18:97-108. doi: 10.2147/DDDT.S435522. eCollection 2024. Drug Des Devel Ther. 2024. PMID: 38264539 Free PMC article. Review.
• ROCK and PDE-5 Inhibitors for the Treatment of Dementia: Literature Review and Meta-Analysis.
  Lee DH, Lee JY, Hong DY, Lee EC, Park SW, Jo YN, Park YJ, Cho JY, Cho YJ, Chae SH, Lee MR, Oh JS. Lee DH, et al. Biomedicines. 2022 Jun 8;10(6):1348. doi: 10.3390/biomedicines10061348. Biomedicines. 2022. PMID: 35740369 Free PMC article. Review.
• Neuroblastoma Heterogeneity, Plasticity, and Emerging Therapies.
  Lundberg KI, Treis D, Johnsen JI. Lundberg KI, et al. Curr Oncol Rep. 2022 Aug;24(8):1053-1062. doi: 10.1007/s11912-022-01270-8. Epub 2022 Apr 1. Curr Oncol Rep. 2022. PMID: 35362827 Free PMC article. Review.
• Gα12 overexpression in hepatocytes by ER stress exacerbates acute liver injury via ROCK1-mediated miR-15a and ALOX12 dysregulation.
  Tak J, Kim YS, Kim TH, Park GC, Hwang S, Kim SG. Tak J, et al. Theranostics. 2022 Jan 9;12(4):1570-1588. doi: 10.7150/thno.67722. eCollection 2022. Theranostics. 2022. PMID: 35198058 Free PMC article.

References

1. 1. Ishizaki T, Maekawa M, Fujisawa K, Okawa K, Iwamatsu A, Fujita A, Watanabe N, Saito Y, Kakizuka A, Morii N, Narumiya S. The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J. 1996;15:1885–1893. - PMC - PubMed
2. 1. Leung T, Manser E, Tan L, Lim L. A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes. J Biol Chem. 1995;270:29051–29054. doi: 10.1074/jbc.270.49.29051. - DOI - PubMed
3. 1. Matsui T, Amano M, Yamamoto T, Chihara K, Nakafuku M, Ito M, Nakano T, Okawa K, Iwamatsu A, Kaibuchi K. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J. 1996;15:2208–2216. - PMC - PubMed
4. 1. Nakagawa O, Fujisawa K, Ishizaki T, Saito Y, Nakao K, Narumiya S. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett. 1996;392:189–193. doi: 10.1016/0014-5793(96)00811-3. - DOI - PubMed
5. 1. Amano M, Ito M, Kimura K, Fukata Y, Chihara K, Nakano T, Matsuura Y, Kaibuchi K. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase) J Biol Chem. 1996;271:20246–20249. doi: 10.1074/jbc.271.34.20246. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • PubMed Central
  • Springer

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information